AstraZeneca Licenses Lung Cancer Drug Zegfrovy from Dizal Pharmaceutical

What happened

AstraZeneca secured worldwide rights to develop and commercialise Zegfrovy from Dizal Pharmaceutical through a licensing agreement worth $600 million upfront and up to $900 million in development, regulatory, and sales milestones. Dizal will retain tiered royalties on global sales. Zegfrovy is an oral EGFR inhibitor approved in the US and China for treating adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations whose disease progressed after platinum-based chemotherapy. The drug generated approximately $83.4 million in revenue for Dizal in 2025, representing an 85% year-over-year increase, largely driven by US accelerated approval in July 2025 following its August 2023 approval in China. Supplemental applications for first-line use have been submitted to the FDA and China's CDE based on positive results from Dizal's global WU-KONG28 Phase III trial, which demonstrated improved progression-free survival compared to platinum-based chemotherapy. These results were presented at the 2026 ASCO Annual Meeting and published in The New England Journal of Medicine. The transaction is expected to close in the second half of 2026 pending regulatory clearance.

Why it matters

This acquisition strengthens AstraZeneca's position in EGFR-mutated lung cancer treatment by adding a revenue-generating asset with significant expansion potential. Zegfrovy targets patients with exon 20 insertion mutations, a subset historically underserved by targeted therapies, representing a distinct unmet need within NSCLC. The drug's oral formulation offers a differentiated alternative to Johnson & Johnson's Rybrevant, currently the only approved first-line treatment for this mutation type, which requires intravenous administration combined with chemotherapy. If approved for first-line use, Zegfrovy could capture meaningful market share in a growing segment, given that NSCLC accounts for 80-85% of all lung cancer cases and lung cancer remains the leading cause of cancer death globally. The deal adds immediate commercial value while offering long-term growth through label expansion, complementing AstraZeneca's existing lung cancer franchise that includes blockbuster Tagrisso.

Bigger picture

This transaction marks AstraZeneca's second major licensing deal in China within a month, reflecting the growing trend of Western pharmaceutical companies sourcing innovation from Chinese biotech firms. The move highlights China's emergence as a competitive source of oncology assets, particularly in targeted therapies addressing specific genetic mutations. The deal also underscores intensifying competition in the precision oncology space, where companies are racing to develop treatments for molecularly defined patient populations. With lung cancer causing roughly one in five cancer deaths worldwide, the commercial opportunity for effective targeted therapies remains substantial. AstraZeneca's willingness to pay a significant premium for a drug already on the market signals confidence in both Zegfrovy's clinical profile and the broader shift toward oral targeted treatments that improve patient convenience compared to infusion-based therapies.

What to watch

Key upcoming catalysts include regulatory decisions from the FDA and China's CDE on Zegfrovy's first-line indication applications, which would significantly expand its addressable patient population and commercial potential. Investors should monitor the drug's sales trajectory following potential label expansion and its competitive positioning against Rybrevant in head-to-head clinical or real-world settings. Additional clinical data presentations or publications could further validate Zegfrovy's efficacy and safety profile. The transaction's completion in the second half of 2026 will depend on securing necessary regulatory clearances. Longer term, watch for AstraZeneca's broader strategy in licensing assets from Chinese biotechs and how Zegfrovy integrates with its existing lung cancer portfolio, particularly any combination studies with Tagrisso or other pipeline candidates.